COVID-19. COVID-19, virus identified
Conditions
Interventions
Intervention 1: Individuals in the intervention group approved by the nationally approved hydroxychloroquine regimen as a single dose and then daily administration of Kaletra and in addition to the ab
Sponsors
Dezfoul University of Medical Sciences
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Inclusion criteria
Inclusion criteria: Individuals over 18 years of age whose covid-19 disease has been confirmed by PCR test (PCR specification of the test from the Iranian manufacturer - Pishtaz Teb and performed by molecular method) and clinically severely ill o2sat below 90% despite receiving oxygen Severe bilateral pulmonary involvement Satisfaction to participate in the study Failure to receive any medication other than the standard protocol approved by the National Corona Therapy
Exclusion criteria
Exclusion criteria: History of drug allergies to similar compounds Pregnancy and lactation Infection with other microbial or viral infections History of heart disease
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Clinical efficacy according to clinical response based on blood oxygen saturation. Timepoint: Daily. Method of measurement: Pulse oximetry.;LDH levels. Timepoint: Three times a week. Method of measurement: laboratory test.;Duration of hospitalization. Timepoint: End of treatment. Method of measurement: Patient file.;Mortality rate. Timepoint: Daily. Method of measurement: Patient file.;Changes in liver enzymes. Timepoint: twice a week. Method of measurement: laboratory test.;Clinical efficacy of treatment regimen based on changes in respiratory rate. Timepoint: Daily. Method of measurement: Patient record and clinical examination. | — |
Secondary
| Measure | Time frame |
|---|---|
| Lung involvement status. Timepoint: Weekly. Method of measurement: Interpretation of CT scan. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactLeila Masoudi Yekta
Dezfoul University of Medical Sciences
Outcome results
None listed